ID   JJ012
AC   CVCL_D605
SY   JJO12; JJ
DR   BTO; BTO:0005168
DR   EFO; EFO_0006604
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03470880
DR   cancercelllines; CVCL_D605
DR   Cosmic; 1602476
DR   Cosmic; 1992323
DR   EGA; EGAS00001000610
DR   GEO; GSM1676351
DR   GEO; GSM1701681
DR   IARC_TP53; 27035
DR   PharmacoDB; JJ012_705_2019
DR   Wikidata; Q54898950
RX   PubMed=8689637;
RX   PubMed=10906887;
RX   PubMed=12168675;
RX   PubMed=12354749;
RX   PubMed=19787792;
RX   PubMed=22057234;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26368816;
RX   PubMed=26589293;
CC   Doubling time: 0.9 day (PubMed=12168675).
CC   HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,05:01 (PubMed=26589293).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Gly (c.394C>G); ClinVar=VCV000375892; Zygosity=Heterozygous (PubMed=22057234; PubMed=26368816).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly199Val (c.596G>T); ClinVar=VCV000451799; Zygosity=Unspecified (PubMed=19787792).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
ST   Source(s): PubMed=19787792; PubMed=25877200
ST   Amelogenin: X (PubMed=25877200)
ST   Amelogenin: X,Y (PubMed=19787792)
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 15 (PubMed=25877200)
ST   D18S51: 15,17 (PubMed=19787792)
ST   D19S433: 12,13
ST   D21S11: 28,29
ST   D2S1338: 20,23
ST   D3S1358: 15,16,17,18 (PubMed=25877200)
ST   D3S1358: 16,17 (PubMed=19787792)
ST   D5S818: 11,12
ST   D7S820: 8,10
ST   D8S1179: 13
ST   FGA: 21,22
ST   Penta D: 11,13
ST   Penta E: 7,15
ST   SE33: 20.2,21
ST   TH01: 6,8
ST   TPOX: 8,9
ST   vWA: 15,16 (PubMed=25877200)
ST   vWA: 15,19 (PubMed=19787792)
DI   NCIt; C7155; Primary central chondrosarcoma
DI   ORDO; Orphanet_55880; Chondrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   39Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 26
//
RX   PubMed=8689637; DOI=10.1016/0304-3835(96)04274-7;
RA   Jagasia A.A., Block J.A., Qureshi A., Diaz M.O., Nobori T.,
RA   Gitelis S., Iyer A.P.;
RT   "Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2
RT   putative tumor suppressor genes in human chondrosarcomas.";
RL   Cancer Lett. 105:91-103(1996).
//
RX   PubMed=10906887; DOI=10.1097/00003086-200007000-00038;
RA   Scully S.P., Berend K.R., Toth A., Qi W.-N., Qi Z., Block J.A.;
RT   "Interstitial collagenase gene expression correlates with in vitro
RT   invasion in human chondrosarcoma.";
RL   Clin. Orthop. Relat. Res. 376:291-303(2000).
//
RX   PubMed=12168675; DOI=10.1016/S0736-0266(01)00172-3;
RA   Ghert M.A., Qi W.-N., Erickson H.P., Block J.A., Scully S.P.;
RT   "Tenascin-C expression and distribution in cultured human chondrocytes
RT   and chondrosarcoma cells.";
RL   J. Orthop. Res. 20:834-841(2002).
//
RX   PubMed=12354749;
RA   Martin J.A., Forest E., Block J.A., Klingelhutz A.J., Whited B.,
RA   Gitelis S., Wilkey A., Buckwalter J.A.;
RT   "Malignant transformation in human chondrosarcoma cells supported by
RT   telomerase activation and tumor suppressor inactivation.";
RL   Cell Growth Differ. 13:397-407(2002).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=22057234; DOI=10.1038/ng.1004;
RA   Pansuriya T.C., van Eijk R., d'Adamo P., van Ruler M.A.J.H.,
RA   Kuijjer M.L., Oosting J., Cleton-Jansen A.-M., van Oosterwijk J.G.,
RA   Verbeke S.L.J., Meijer D., van Wezel T., Nord K.H., Sangiorgi L.,
RA   Toker B., Liegl-Atzwanger B., San-Julian M., Sciot R., Limaye N.,
RA   Kindblom L.-G., Daugaard S., Godfraind C., Boon L.M., Vikkula M.,
RA   Kurek K.C., Szuhai K., French P.J., Bovee J.V.M.G.;
RT   "Somatic mosaic IDH1 and IDH2 mutations are associated with
RT   enchondroma and spindle cell hemangioma in Ollier disease and Maffucci
RT   syndrome.";
RL   Nat. Genet. 43:1256-1261(2011).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26368816; DOI=10.1371/journal.pone.0133813;
RA   Li L.-Y., Paz A.C., Wilky B.A., Johnson B., Galoian K., Rosenberg A.,
RA   Hu G.-Z., Tinoco G., Bodamer O.A., Trent J.C. II;
RT   "Treatment with a small molecule mutant IDH1 inhibitor suppresses
RT   tumorigenic activity and decreases production of the oncometabolite
RT   2-hydroxyglutarate in human chondrosarcoma cells.";
RL   PLoS ONE 10:E0133813-E0133813(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//